Entering text into the input field will update the search result below

Cytokinetics, Inc. (CYTK) CEO Robert Blum on Q1 2020 Results - Earnings Call Transcript

May 06, 2020 10:24 PM ETCytokinetics, Incorporated (CYTK)
SA Transcripts profile picture
SA Transcripts

Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET

Company Participants

Diane Weiser - VP, IR & Corporate Communications

Robert Blum - CEO, President & Director

Fady Malik - EVP, Research & Development

Stuart Kupfer - Chief Medical Officer

Robert Wong - VP & CAO

Ching Jaw - SVP & CFO

Conference Call Participants

Joe Pantginis - H.C. Wainwright

Jason Butler - JMP Securities

Chad Messer - Needham & Company

Ted Tenthoff - Piper Sandler

Jeff Hung - Morgan Stanley


Good afternoon, and welcome ladies and gentlemen, to Cytokinetics' First Quarter 2020 Conference Call. At this time, I'd like to inform you that this call is being recorded, and that all participants are in a listen-only mode. At the company's request we will open the call for question-and-answers after the presentation.

I'll now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser

Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and the impact of COVID-19 on certain clinical trials. Then Fady Malik, our EVP of Research and Development, will provide updates on key developments for omecamtiv mecarbil, our cardiac myosin activator, and AMG 594, our cardiac troponin activator, both under our collaboration with Amgen.

Next, Stuart Kupfer our SVP and Chief Medical Officer will update on recent progress with CK-274, our wholly-owned cardiac myosin inhibitor now in Phase II, and CK-271, our additional cardiac myosin inhibitor.

Then Robert Wong, our VP and Chief Accounting Officer, will provide a financial overview for the quarter, and Ching Jaw, our SVP and Chief Financial Officer, will discuss corporate development strategies before Robert Blum provides concluding thoughts on

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.